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It has been known for considerable time [1] that
microalbuminuria increases the risk of cardiovascular
events and cardiovascular death in diabetic patients. It
has only been relatively recently, however, that the ad-
verse effect of microalbuminuria on cardiovascular risk
in nondiabetic patients has been recognized [2]. The
largest evidence in this respect has been provided by
studies in the general population (e.g., in Groningen [3],
in Tro¨ndelag [4], and Copenhagen [5]). Hillege et al
reported that among 40,856 individuals in the general
population of Groningen (North Holland), 7.2% had mi-
crolbuminuria. The great majority had no comorbidity,
and no less than 6.6% had microalbuminuria without
diabetes or hypertension. It is very likely that the high
normal range of albuminuria already carries cardiovas-
cular risk, as recently reported by Gerstein et al [6] in the
HOPE study, and Wachtell [7] in the LIFE study. They
noted that the risk of cardiovascular events started to in-
crease at albumin excretion rates well below the formal
limit of microalbuminuria (i.e., 20–200 lg/mL or 30–300
mg/day). Such findings in the general population are well
in line with observations of Rachmani, who noted that
for diabetic patients with albumin excretion rates 20 to
300 mg/day (i.e., the high normal range), the risk to de-
velop microalbuminuria or a cardiovascular event was
higher by a factor of 12.4 and 9.8 compared to albumin-
uria 0 to 10 mg/day [8]. It is of note that the prediction of
CV risk by albuminuria is independent of established risk
factors, such as smoking, gender, blood pressure, and oth-
ers, as noted in the Copenhagen study by Borch-Johnsen
[5].
Of particular interest is the known link between mi-
croalbuminuria and the metabolic syndrome. Verhave
et al [9] noted a striking relation, more so in male than
in female individuals, between fasting blood glucose con-
centration and urinary albumin excretion, as well as be-
tween BMI and urinary albumin excretion. What is of
great interest is the observation that this is true not
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only for elevated glucose or BMI values; the correla-
tion extends well into the range of normal values. Appar-
ently, the metabolic syndrome and microalbuminuria are
tightly correlated with each other. This relation is of con-
siderable interest because in patients with renal disease
insulin resistance is found even in the very early stages
[10], and even when GFR is still within the normal range
(unpublished observations). Conversely, in a population
sample it was found that insulin resistance (according to
the HOMA index) was associated with a higher risk of
chronic kidney disease [11]. The information obtained
from microalbuminuria cannot be replaced by estimating
the glomerular filtration rate. Although the reports in the
literature are not entirely consistent, the study in Gronin-
gen showed that with increasing quantiles of urinary al-
bumin excretion, the creatinine clearance tended to be
higher and was lower only in the uppermost quantiles
[12]. Although the creatinine clearance is not a reliable
index of glomerular filtration, this observation would be
plausible in view of a similar relation between GFR and
albuminuria noted previously in diabetic patients [13].
There has been much discussion whether microalbu-
minuria reflects primarily a generalized endothelial cell
dysfunction, as suggested by the Steno hypothesis [14], or
whether it reflects a podocyte defect, as proposed more
recently [15]. The observation that the rate of albumin es-
cape from the plasma space is increased in patients with
microalbuminuria [16] argues for the former possibility.
The observation that the risk of being microalbuminuric
was significantly higher for carriers of the Q-genotype of
the 229 polymorphism of the podocin gene at any given
level of body mass index or other correlates of microal-
buminuria is more in favor of a podocyte problem [15].
eGFR and cardiovascular risk
To the best of our knowledge, one of the first stud-
ies to clearly document the relation between serum
creatinine concentration and mortality was the obser-
vation of Shulman [17] in the Hypertension Detection
and Follow-Up program. Over 96 months of follow-up,
the cumulative life mortality increased progressively with
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increasing serum creatinine concentration between 1.2 to
2.5 mg/dL. This information is important because recent
studies based mainly on NHANES data show that minor
renal dysfunction is extremely prevalent in the United
States population. Three percent of the population is
estimated to have chronic kidney disease stage 2 (i.e.,
eGFR 60–89 mL/min), and 4.3% stage 3 (i.e., eGFR of
30–59 mL/min).
Meanwhile, the relation between reduced glomerular
filtration and cardiovascular risk has been shown in the
general population, in hypertensive patients, in individu-
als at high cardiovascular risk, and in patients with cardiac
dysfunction, specifically congestive heart failure. Further-
more, substantial evidence indicated that during and af-
ter acute cardiac ischemic events, the mortality is strongly
dependent on renal function.
In a prospective population-based study in the Dutch
city of Hoorn in individuals age 50 to 75 years, Henry
[18] found that the relative risk of a cardiovascular death
increased by 26% per 5 mL/min/1.73m2 lower GFR. This
indicates that a difference in eGFR of 20 mL/min is as-
sociated with a 2-fold increase in the risk of CV death.
Ruilope [19] found in individuals recruited for the HOT
study (Hypertension Optimal Treatment) that patients
with an estimated creatinine clearance less than 60 mL/
min. consistently had almost double the events per
1000 patient years compared to patients with creatinine
clearance >60 mL/min, independent of the target dias-
tolic blood pressure to which these patients had been
randomized.
The HOPE study [20] investigated individuals at high
cardiovascular risk. The analysis of the relation be-
tween serum creatinine concentration and cardiovascular
events [21] showed a strong correlation between serum
creatinine and the event rate. The hazard ratio for a pa-
tient with a serum creatinine 1.4 to 2.0 mg/dL was higher
by 40%, for the patient with microalbuminuria by 59%,
and for the patient with both increased serum creatinine
and microalbuminuria by 108%. This should be com-
pared to diabetes, per se, which increased the risk only
by 42%.
In patients with congestive heart failure (CHF), eGFR
emerged as a potent and independent predictor of car-
diovascular risk. Hillege [22] analyzed 1906 patients with
CHF who had been enrolled in a prospective randomized
survival trial. Baseline eGFR, according to Cockcroft-
Gault, was the single most potent predictor of risk, fol-
lowed by NYHA class and use of ACE inhibitors. The
negative impact of low eGFR on survival was found for
each category of NYHA class and EF, so that eGFR is
not merely a surrogate marker for the severity of heart
failure, but an independent predictor of risk.
Patients undergoing an ischemic event have much
more adverse outcomes if serum creatinine concentra-
tions are elevated. In a Medicare sample, Shlipak et al
[23] noted a strong dependence of post-discharge sur-
vival on serum creatinine concentrations in the range
<1.5 to 3.9 mg/dL. In a single center study, Wright [24]
analyzed 3106 patients and found a strong relation be-
tween eCcr and in-hospital mortality, ranging from 2%
at eGFR >75 mL/min, 6% at 50 to 75 mL/min, 14% at 35
to 50 mL/min, up to 30% in end-stage renal disease. Sim-
ilarly, a high post-discharge death hazard ratio was noted
(2.4 at eCcr 50–75 mL/min compared to >75 mL/min and
5.4 with end-stage renal disease). The risk of in-hospital
death increased already when eCcr was 80 compared to
110 mL/min. This observation has recently been con-
firmed in a large international, prospective, multicen-
ter study covering 11,715 patients. The relative risk of
death was 4.7 at an eCcr of 30 to 60 mL/min, and 9.92
at <30 mL/min compared to patients with eCcr >60 mL/
min [25]. Reineke [26] noted a striking relation between
serum creatinine concentration and cumulative mortality
in patients who had undergone PTCA. The risk increased
from 5% at S-creatinine <1.0, and 6.3% at 1.1 mg/dL, and
9% at 1.2 mg/dL, to no less than 31% at a serum creatinine
>2 mg/dL.
Serum creatinine is a notoriously insensitive reflec-
tion of glomerular filtration. It is strikingly influenced by
muscle mass and other confounding factors. It has there-
fore been recommended to use algorithms to estimate
routinely the GFR with the help of the Cockroft-Gault
formula [27] or the MDRD formula [28]. None of these
formulas is absolutely satisfactory [29], but their use is a
decided progress compared to reliance on serum creati-
nine alone, and has now been more widely proposed in
consensus statements [30, 31].
Pathomechanisms
The high cardiovascular risk conferred by minor renal
dysfunction could possibly be explained by the known
endothelial cell dysfunction in incipient renal disease.
There are several observations that point in this direc-
tion. First, Kielstein et al found that the concentrations
of asymmetric dimethyl L-arginine are increased in re-
nal patients, even when the inulin clearance is still within
the normal range [32]. We have found a striking relation
between symmetric dimethyl-L-arginine and serum cre-
atinine, but not between ADMA and serum creatinine.
Therefore, we postulated that it is not (only) impaired
renal excretion, but also impaired catabolism that con-
tributes to high ADMA concentrations in renal disease
[33]. This postulate is in line with recent demonstrations
that endothelial dysfunction is associated with dysreg-
ulation of dimethyl-L-arginine dimethylaminohydrolase
[34].
With respect to the cardiovascular risk, it is partic-
ularly important that even at normal GFR, hyperten-
sive individuals with ADPKD have strikingly increased
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sympathetic activity when measured by microneurogra-
phy [35].
There is also recent evidence of increased biomark-
ers of inflammation such as CRP, fibrinogen, IL-6, and
ICAM, as well as indicators of a procoagulatory state
(factor VIII, D-dimers) [36], and this has been confirmed
in the Birmingham study [37].
Furthermore, even when GFR is still normal, Stefan-
ski et al [38] found increased blood pressure values by
ambulatory blood pressure measurements, particularly,
increased nighttime values, and this was associated with
evidence of target organ damage (i.e., thickening of the
LV wall and evidence of diastolic LV malfunction).
Finally, abnormal lipoprotein patterns are present in
renal patients again, even when GFR is still normal [39,
40].
Recently, two groups provided evidence for acceler-
ated atherogenesis in renal failure using the apo-E knock-
out mouse model [41, 42]. Slight reduction of functional
renal parenchyma by uninephrectomy caused marked ac-
celeration of the rate of growth of plaques. This was as-
sociated with expression of nitrotyrosine as an indicator
of oxidative stress in aortic endothelial cells [41], as well
as with increased expression of adhesion molecules [42].
CONCLUSION
We propose the hypothesis that such minor derange-
ments of renal function, as reflected by microalbumin-
uria or reduced glomerular filtration, cause an increase in
oxidative stress, thus provoking dysfunction of endothe-
lial cells. It is plausible to assume that this sensitizes the
vasculature to further damage when they are exposed to
the injurious effect of hypertension, dyslipidemia, hyper-
glycemia, or smoking.
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